Influence of NU1025 on survival of animals treated with TZM
| Treatment . | No. mice . | MST (range) . | ILS† (vs CTR) (%) . | P‡(vs CTR) . | ILS2-153 (vs TZM) (%) . | P‡ (vs TZM) . |
|---|---|---|---|---|---|---|
| CTR | 14 | 17 (12-21) | — | — | — | — |
| NU 1025 ip | 10 | 17 (15-19) | — | NS | — | — |
| NU1025 ic | 14 | 16 (12-21) | — | NS | — | — |
| TZM (100 mg/kg) | 14 | 18 (15-21) | 6 | NS | — | — |
| TZM (200 mg/kg) | 14 | 18 (15-19) | 6 | NS | — | — |
| TZM (100 mg/kg) twice* | 14 | 19 (15-22) | 12 | NS | — | — |
| NU1025 ip + TZM (100 mg/kg) twice* | 10 | 17 (15-20) | — | NS | — | — |
| NU1025 ic + TZM (100 mg/kg) | 14 | 23 (19-> 90)2-155 | 35 | < .0001 | 28 | < .0001 |
| NU1025 ic + TZM (200 mg/kg) | 14 | 23 (15-> 90)2-155 | 35 | < .0001 | 28 | .0002 |
| NU1025 ic + TZM (100 mg/kg) twice* | 14 | 27 (19-> 90)2-155 | 59 | < .0001 | 42 | < .0001 |
| Treatment . | No. mice . | MST (range) . | ILS† (vs CTR) (%) . | P‡(vs CTR) . | ILS2-153 (vs TZM) (%) . | P‡ (vs TZM) . |
|---|---|---|---|---|---|---|
| CTR | 14 | 17 (12-21) | — | — | — | — |
| NU 1025 ip | 10 | 17 (15-19) | — | NS | — | — |
| NU1025 ic | 14 | 16 (12-21) | — | NS | — | — |
| TZM (100 mg/kg) | 14 | 18 (15-21) | 6 | NS | — | — |
| TZM (200 mg/kg) | 14 | 18 (15-19) | 6 | NS | — | — |
| TZM (100 mg/kg) twice* | 14 | 19 (15-22) | 12 | NS | — | — |
| NU1025 ip + TZM (100 mg/kg) twice* | 10 | 17 (15-20) | — | NS | — | — |
| NU1025 ic + TZM (100 mg/kg) | 14 | 23 (19-> 90)2-155 | 35 | < .0001 | 28 | < .0001 |
| NU1025 ic + TZM (200 mg/kg) | 14 | 23 (15-> 90)2-155 | 35 | < .0001 | 28 | .0002 |
| NU1025 ic + TZM (100 mg/kg) twice* | 14 | 27 (19-> 90)2-155 | 59 | < .0001 | 42 | < .0001 |
NS indicates not significant.
Sequential treatment with TZM (100 mg/kg) on days 2 and 3.
ILS of drug-treated mice was calculated (see “Study design”) comparing their MST with those of control animals injected with drug vehicles only (CTR).
P was calculated comparing survival curves (see “Statistical analysis”) of drug-treated groups versus CTR, or comparing survival curves of mice treated with the drug combination versus mice treated with the corresponding dose and schedule of TZM.
ILS of mice treated with NU1025 intracranially (ic) + TZM was calculated comparing their MST with those of mice treated with TZM only. In particular, ILS of animals treated with NU1025 + 100 mg/kg or 200 mg/kg TZM was calculated comparing their MST with those of animals treated with 100 mg/kg or 200 mg/kg TZM, respectively. ILS of animals treated with NU1025 + 100 mg/kg TZM twice was calculated comparing their MST with those of animals treated with TZM (100 mg/kg) twice.
In each of the groups treated with NU1025 intracranially and TZM intraperitoneally (ip), one animal survived more than 90 days.